Download PDF
CC BY 4.0 · Rev Bras Ginecol Obstet 2023; 45(08): e474-e479
DOI: 10.1055/s-0043-1772180
Original Article
Sexually Transmitted Infections/Oncology

Human Papillomavirus 16 Lineage D is Associated with High Risk of Cervical Cancer in the Brazilian Northeast Region

Papillomavirus humano 16 da linhagem D associado a alto risco de câncer de colo do útero em região do nordeste brasileiro
Luís Felipe Leite Martins 
1   Cancer Surveillance and Data Analysis Division, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil
,
Miguel Ângelo Martins Moreira 
2   Tumor Genetics and Virology Program, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil
,
Rodrigo Alves Pinto 
3   Instituto de Medicina Integral Prof. Fernando Figueira, Recife, PE, Brazil
,
Neilane Bertoni dos Reis 
4   Division of Population Research, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil
,
Shayany Pinto Felix 
2   Tumor Genetics and Virology Program, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil
,
João Paulo Castello Branco Vidal 
5   Universidade Federal do Maranhão, São Luis, MA, Brazil
,
Leuridan Cavalcante Torres 
3   Instituto de Medicina Integral Prof. Fernando Figueira, Recife, PE, Brazil
,
Ariani Impieri Souza 
3   Instituto de Medicina Integral Prof. Fernando Figueira, Recife, PE, Brazil
,
Liz Maria de Almeida 
6   Coordination of Prevention and Surveillance, Instituto Nacional do Câncer, Rio de Janeiro, RJ, Brazil
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective Similar to Human Papillomavirus (HPV) genotypes, different lineages of a genotype also have different carcinogenic capabilities. Studies have shown that specific genotype lineages of oncogenic HPV are associated with variable risks for the development of cervical intraepithelial neoplasia (CIN2/CIN3) and cervical cancer. The present study aimed to analyze the genetic diversity of the HPV16 genotype in women with CIN2/CIN3 and cervical cancer, from the northeast region of Brazil.

Methods A cross-sectional multicenter study was conducted in the northeast region of Brazil, from 2014 to 2016. This study included 196 cases of HPV16 variants (59 and 137 cases of CIN2/CIN3 and cervical cancer, respectively). The difference of proportion test was used to compare patients with CIN2/CIN3 and cervical cancer, based on the prevalent HPV16 lineage (p < 0.05).

Results According to the histopathological diagnosis, the percentage of lineage frequencies revealed a marginal difference in the prevalence of lineage A in CIN2/CIN3, compared with that in cervical cancer (p = 0.053). For lineage D, the proportion was higher in cancer cases (32.8%), than in CIN2/CIN3 cases (16.9%), with p = 0.023.

Conclusion HPV16 lineage A was the most frequent lineage in both CIN2/CIN3 and cervical cancer samples, while lineage D was predominant in cervical cancer, suggesting a possible association between HPV16 lineage D and cervical cancer.

Resumo

Objetivo Tanto os tipos quanto as linhagens do Papilomavírus Humano (HPV) parecem ter diferentes capacidades carcinogênicas e estão associados a riscos variados para o desenvolvimento de neoplasia intraepitelial cervical (NIC) e câncer de colo do útero. O presente estudo tem como objetivo analisar a diversidade genética do genótipo HPV 16 nos casos de NIC2/NIC3 e câncer de colo de útero em mulheres da região Nordeste do Brasil.

Métodos Estudo transversal de base hospitalar realizado na região Nordeste do Brasil no período de 2014 a 2016. A amostra foi composta por 196 casos da variante HPV-16 (59 casos de NIC2/NIC3 e 137 de câncer do colo do útero). O teste de diferença de proporção foi usado para comparar os grupos NIC2/NIC3 e câncer de colo do útero por linhagem viral em relação à prevalência da linhagem HPV-16. Foi considerada significância estatística o valor de p < 0,05.

Resultados As frequências de linhagem por diagnóstico histopatológico mostraram diferença limítrofe da linhagem A no grupo NIC2/NIC3 em relação ao grupo câncer de colo de útero (p = 0,053). Por outro lado, em relação à linhagem D, houve uma proporção maior nos casos de câncer (32,8%) quando comparado ao grupo NIC2/NIC3 (16,9%) e esta diferença se mostrou estatisticamente significante (p = 0,023).

Conclusão A linhagem A do HPV-16 foi a mais frequente tanto nas amostras CIN2/CIN3 quanto nas amostras de câncer de colo de útero, enquanto a linhagem D predominou no câncer de colo do útero, sugerindo uma possível associação da linhagem D de HPV-16 com câncer de colo de útero.

Keywords

HPV16 - lineage A - lineage D - CIN2/CIN3 - cervical cancer

Palavras-chave

HPV16 - linhagem A - linhagem D - NIC2/NIC3 - câncer colo útero

Contributions

Martins L. F. L.: Conceptualization, Methodology, Formal analysis, Writing– Original Draft, Writing– Review and Editing. Moreira M. A. M.: Supervision, Conceptualization, Writing– Original Draft, Writing– Review and Editing. Pinto R. A.: Conceptualization, Writing– Original Draft, Writing– Review. Reis N. B.: Methodology, Writing– Original Draft, Writing– Review and Editing. Felix S. P.: Performed the Experiments, Writing– Review and Editing. Vidal J. P. C. B.: Performed the experiments, Writing– Review and Editing. Torres L. C.: Supervision, Performed the experiments, Writing– Review and Editing. Souza A. I.: Conceptualization, Writing– Original Draft, Writing– Review and Editing. Almeida L. M.: Project administration, Funding acquisition, Conceptualization, Writing– Original Draft, Writing– Review and Editing.




Publication History

Received: 06 January 2023

Accepted: 08 March 2023

Article published online:
08 September 2023

© 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249 DOI: 10.3322/caac.21660.
    Google Scholar
  • 2 INCA, Instituto Nacional de Câncer. Estimativa 2022: incidência de câncer no Brasil / Instituto Nacional de Câncer. – Rio de Janeiro: INCA, 2019. Available on: https://www.gov.br/inca/pt-br/assuntos/cancer/numeros/estimativa
    PubMedGoogle Scholar
  • 3 INCA, Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Divisão de Informação. Atlas de mortalidade por câncer: versão 2014. Rio de Janeiro: INCA, 2014 . Available on: < https://www.inca.gov.br/app/mortalidade >. Available: 21 dec. 2022
    PubMedGoogle Scholar
  • 4 Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8 DOI: 10.1186/1750-9378-4-8.
    CrossrefPubMedGoogle Scholar
  • 5 Xi LF, Koutsky LA, Hildesheim A, Galloway D, Wheeler CM, Winer RL. et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev 2007; 16 (01) 4-10 DOI: 10.1158/1055-9965.EPI-06-0670.
    CrossrefPubMedGoogle Scholar
  • 6 Ortiz-Ortiz J, Alarcón-Romero LdelC, Jiménez-López MA, Garzón-Barrientos VH, Calleja-Macías I, Barrera-Saldaña HA. et al. Association of human papillomavirus 16 E6 variants with cervical carcinoma and precursor lesions in women from Southern Mexico. Virol J 2015; 12: 29 DOI: 10.1186/s12985-015-0242-3.
    CrossrefPubMedGoogle Scholar
  • 7 Mirabello L, Yeager M, Cullen M, Boland JF, Chen Z, Wentzensen N. et al. HPV16 Sublineage Associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 Women. J Natl Cancer Inst 2016; 108 (09) djw100 DOI: 10.1093/jnci/djw100.
    CrossrefPubMedGoogle Scholar
  • 8 Clifford GM, Tenet V, Georges D, Alemany L, Pavón MA, Chen Z. et al. Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Res 2019; 7: 67-74 DOI: 10.1016/j.pvr.2019.02.001.
    CrossrefPubMedGoogle Scholar
  • 9 Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP. et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 1993; 67 (11) 6413-6423 DOI: 10.1128/JVI.67.11.6413-6423.1993.
    CrossrefPubMedGoogle Scholar
  • 10 Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX. et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997; 71 (03) 2463-2472 DOI: 10.1128/JVI.71.3.2463-2472.1997.
    CrossrefPubMedGoogle Scholar
  • 11 Arias-Pulido H, Peyton CL, Torrez-Martínez N, Anderson DN, Wheeler CM. Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology 2005; 338 (01) 22-34 DOI: 10.1016/j.virol.2005.04.022.
    CrossrefPubMedGoogle Scholar
  • 12 Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS. et al; IARC HPV Variant Study Group. Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol 2012; 86 (12) 6855-6861 DOI: 10.1128/JVI.00483-12.
    CrossrefPubMedGoogle Scholar
  • 13 Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology 2013; 445 (1-2): 232-243 DOI: 10.1016/j.virol.2013.07.018.
    CrossrefPubMedGoogle Scholar
  • 14 Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL. et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007; 120 (08) 1763-1768 DOI: 10.1002/ijc.22481.
    CrossrefPubMedGoogle Scholar
  • 15 Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T. et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000; 81 (Pt 12): 2959-2968 DOI: 10.1099/0022-1317-81-12-2959.
    CrossrefPubMedGoogle Scholar
  • 16 Freitas LB, Chen Z, Muqui EF, Boldrini NAT, Miranda AE, Spano LC. et al. Human papillomavirus 16 non-European variants are preferentially associated with high-grade cervical lesions. PLoS One 2014; 9 (07) e100746 DOI: 10.1371/journal.pone.0100746.
    CrossrefPubMedGoogle Scholar
  • 17 Junes-Gill K, Sichero L, Maciag PC, Mello W, Noronha V, Villa LL. Human papillomavirus type 16 variants in cervical cancer from an admixtured population in Brazil. J Med Virol 2008; 80 (09) 1639-1645
    CrossrefPubMedGoogle Scholar
  • 18 Tornesello ML, Losito S, Benincasa G. et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 2011; 121 (01) 32-42 DOI: 10.1016/j.ygyno.2010.12.005.
    CrossrefPubMedGoogle Scholar
  • 19 Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B. et al. HPV16 E7 Genetic conservation is critical to carcinogenesis. Cell 2017; 170 (06) 1164-1174.e6 DOI: 10.1016/j.cell.2017.08.001.
    CrossrefPubMedGoogle Scholar
  • 20 Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S. et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012; 104 (22) 1738-1749 DOI: 10.1093/jnci/djs425.
    CrossrefPubMedGoogle Scholar
  • 21 de Almeida LM, Martins LFL, Pontes VB, Corrêa FM, Montenegro RC, Pinto LC. et al. Human Papillomavirus Genotype Distribution among Cervical Cancer Patients prior to Brazilian National HPV Immunization Program. J Environ Public Health 2017; 2017: 1645074 DOI: 10.1155/2017/1645074.
    CrossrefPubMedGoogle Scholar
  • 22 Pontes VB, Martins LFL, Szklo M, Moreira MÂM, Chaves CBP, de Almeida LM. Factors associated with cervical intraepithelial neoplasia (CIN2/CIN3), early stage and advanced stage of cervical cancer diagnosis in the Brazilian Amazonian region. Eur J Cancer Prev 2020; 29 (04) 342-345 DOI: 10.1097/CEJ.0000000000000546.
    CrossrefPubMedGoogle Scholar
  • 23 Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A. et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38 (01) 357-361 DOI: 10.1128/JCM.38.1.357-361.2000.
    CrossrefPubMedGoogle Scholar
  • 24 de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76 (Pt 4): 1057-1062 DOI: 10.1099/0022-1317-76-4-1057.
    CrossrefPubMedGoogle Scholar
  • 25 Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215 (03) 403-410 DOI: 10.1016/S0022-2836(05)80360-2.
    CrossrefPubMedGoogle Scholar
  • 26 Vidal JP, Felix SP, Chaves CB, Patury P, Franco VF, Morais EA. et al. Genetic diversity of HPV16 and HPV18 in Brazilian patients with invasive cervical cancer. J Med Virol 2016; 88 (07) 1279-1287 DOI: 10.1002/jmv.24458.
    CrossrefPubMedGoogle Scholar
  • 27 Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89 (02) 229-240 DOI: 10.1016/s0168-1702(02)00191-0.
    CrossrefPubMedGoogle Scholar
  • 28 Karadža M, Židovec Lepej S, Planinić A, Grgić I, Ćorušić A, Planinić Pavao. et al. Distribution of human papillomavirus genotypes in women with high-grade cervical intraepithelial lesions and cervical carcinoma and analysis of human papillomavirus-16 genomic variants. Croat Med J 2021; 62 (01) 68-79 DOI: 10.3325/cmj.2021.62.68.
    CrossrefPubMedGoogle Scholar
  • 29 de Oliveira GR, Vieira VC, Ávila EC, Finger-Jardim F, Caldeira TD, Gatii FA. et al. Human papillomavirus type distribution and HPV16 intratype diversity in southern Brazil in women with and without cervical lesions. Mem Inst Oswaldo Cruz 2017; 112 (07) 492-498 DOI: 10.1590/0074-02760160530.
    CrossrefPubMedGoogle Scholar